Home » Stocks » GANX

Gain Therapeutics, Inc. (GANX)

Stock Price: $9.61 USD 0.61 (6.78%)
Updated May 14, 2021 4:00 PM EDT - Market closed
Market Cap 46.79M
Revenue (ttm) n/a
Net Income (ttm) n/a
Shares Out 4.87M
EPS (ttm) n/a
PE Ratio n/a
Forward PE n/a
Dividend n/a
Dividend Yield n/a
Trading Day May 14
Last Price $9.61
Previous Close $9.00
Change ($) 0.61
Change (%) 6.78%
Day's Open 9.63
Day's Range 9.11 - 9.97
Day's Volume 27,521
52-Week Range 8.75 - 17.93

News

Hide News
  • All
  • Videos
  • Press Releases
  • Conversation

Completed successful initial public offering and raised $46 million in gross proceeds --- Appointed four new independent board of directors to strengthen leadership team --- Signed a multi-target collab...

5 days ago - GlobeNewsWire

Compounds reverse the neurodegenerative process observed in a Parkinson's disease in vivo model

1 week ago - GlobeNewsWire

BETHESDA, Md., April 27, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (NASDAQ: GANX) (“Gain”) a biotechnology company focused on redefining drug discovery by identifying and optimizing allosteric bi...

2 weeks ago - GlobeNewsWire

Abstract highlighting Gain's STAR candidate for Parkinson's disease selected as one of the 10 Best Abstracts at the conference Abstract highlighting Gain's STAR candidate for Parkinson's disease selecte...

3 weeks ago - GlobeNewsWire

Collaboration to use Gain's proprietary Site-Directed Enzyme Enhancement Therapy (SEE-Tx™) computational platform technology to identify new and previously  difficult-to-drug oncology targets

3 weeks ago - GlobeNewsWire

BETHESDA, Md., March 25, 2021 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (“Gain”) today announced the closing of its initial public offering of 3,636,364 shares of its common stock and full exercise of...

1 month ago - GlobeNewsWire

Last week was a busy one for the IPO market with 11 IPOs raising $3 billion, joined by 24 SPACs that brought another $8.4 billion to the table. Chinese IoT platform developer Tuya Inc (NYSE: TUYA) raise...

Other stocks mentioned: AFCG, CNTB, FNCH, JWEL, NAPA, OLO, SNCY ...
1 month ago - Benzinga

Gain Therapeutics, Inc. (“Gain”) today announced the pricing of its initial public offering of...

1 month ago - GlobeNewswire

Gain Therapeutics, Inc. (“Gain”) today announced that it has launched the roadshow for its initial...

2 months ago - GlobeNewswire

Gain Therapeutics, a preclinical biotech developing small molecule therapies for lysosomal storage disorders, filed on Friday with the SEC to raise up to $40 million in an initial public offering.

2 months ago - NASDAQ

Gain Therapeutics, Inc. has filed to go public with an IPO on the NASDAQ.

2 months ago - SEC

About GANX

Gain Therapeutics is a development stage biotechnology company developing novel therapeutics to treat diseases caused by protein misfolding, with an initial focus on lysosomal storage disorders (“LSDs”), including rare genetic diseases and neurological disorders. We use our exclusively in-licensed proprietary platform, Site-Directed Enzyme Enhancement Therapy (“SEE-Tx”), to discover novel allosteric sites on misfolded proteins and identify proprietary small molecules that bind these sites and restore protein folding, potentially treatin... [Read more...]

Industry
Biotechnology
IPO Date
Mar 18, 2021
CEO
Eric I. Richman
Employees
11
Stock Exchange
NASDAQ
Ticker Symbol
GANX
Full Company Profile

Financial Performance

In 2020, GANX's revenue was $28,881, a decrease of -30.07% compared to the previous year's $41,301. Losses were -$3.58 million, 63.1% more than in 2019.

Financial Statements